TABLE 1.
Clinical characteristics of COVID-19 patients in different cohorts
| Clinical features | Value |
||
|---|---|---|---|
| Cohort I (n = 24) | Cohort II (n = 28) | All patients (n = 52) | |
| Sex (no. male/no. female) | 16/8 | 20/8 | 36/16 |
| Age (yrs) (median [IQR]) | 52.50 (30.75–61.00) | 42.50 (31.75–51.50) | 46.50 (31.00–60.00) |
| Nationality (n) | |||
| Chinese | 23 | 27 | 50 |
| African | 1 | 1 | 2 |
| Exposure history (n [%]) | 22 (91.67) | 25 (89.29) | 47 (90.38) |
| Symptoms (n [%]) | |||
| Any | 23 (95.83) | 25 (89.29) | 48 (92.31) |
| Fever | 20 (83.33) | 15 (53.57) | 35 (67.31) |
| Cough or expectoration | 16 (66.67) | 6 (21.43) | 22 (59.62) |
| Muscle pain or fatigue | 3 (12.50) | 9 (32.14) | 12 (42.31) |
| Sore throat | 6 (25.00) | 14 (50.00) | 20 (38.46) |
| Shortness of breath | 6 (25.00) | 5 (17.86) | 11 (21.15) |
| Diarrhea | 3 (12.50) | 5 (17.86) | 8 (15.38) |
| Rhinorrhea | 4 (16.67) | 3 (10.71) | 7 (13.46) |
| Headache | 1 (4.17) | 5 (17.86) | 6 (11.54) |
| Nausea or vomiting | 1 (4.17) | 3 (10.71) | 4 (7.69) |
| Radiologic findings (n [%]) | |||
| Abnormalities on CT | 14 (58.33) | 26 (92.86) | 40 (76.92) |
| Ground-glass opacity | 10 (41.67) | 18 (64.29) | 28 (53.85) |
| Bilateral patchy shadowing | 12 (50.00) | 8 (28.57) | 20 (38.46) |
| Local patchy shadowing | 5 (20.83) | 8 (28.57) | 13 (25.00) |
| Interstitial abnormalities | 1 (4.17) | 12 (42.86) | 13 (25.00) |
| Comorbidities (n [%]) | |||
| Any | 9 (37.50) | 12 (42.86) | 21 (40.38) |
| Hypertension | 4 (16.67) | 4 (14.29) | 8 (15.38) |
| Diabetes | 2 (8.33) | 2 (7.14) | 4 (7.69) |
| Coronary heart disease | 1 (4.17) | 2 (7.14) | 3 (5.77) |
| Bronchitis | 3 (12.50) | 3 (5.77) | |
| Cancer | 2 (8.33) | 2 (3.85) | |
| Hypohepatia | 1 (4.17) | 1 (3.57) | 2 (3.85) |
| Chronic obstructive pulmonary disease | 1 (3.57) | 1 (1.92) | |
| Kidney injury | 1 (3.57) | 1 (1.92) | |
| Coinfection | |||
| Any | 9 (37.50) | 3 (10.71) | 12 (23.08) |
| Mycoplasma | 9 (37.50) | 1 (3.57) | 10 (19.23) |
| Hepatitis B virus infection | 1 (3.57) | 1 (1.92) | |
| Mycobacterium tuberculosis | 1 (3.57) | 1 (1.92) | |
| Influenza A | 1 (4.17) | 1 (1.92) | |
| Clinical classification | |||
| Nonsevere | 22 (91.67) | 27 (96.43) | 49 (94.23) |
| Severe | 2 (8.33) | 1 (3.57) | 3 (3.57) |
| Hematologic abnormalities (n [%]) | |||
| Any | 20 (83.33) | 20 (71.43) | 40 (76.92) |
| C-reactive protein (>5 mg/liter) | 14 (58.33) | 12 (42.86) | 26 (50.00) |
| Lymphocytes (<1.1 × 109/liter or >3.2 × 109/liter) | 12 (50.00) | 5 (17.86) | 17 (32.69) |
| Hemoglobin (<130 g/liter) | 3 (12.50) | 8 (28.57) | 11 (21.15) |
| Neutrophils (<3.5 × 109/liter or >9.5 × 109/liter) | 3 (12.50) | 11 (39.29) | 14 (26.92) |
| Leukocytes (<3.5 × 109/liter or >9.5 × 109/liter) | 4 (16.67) | 5 (17.86) | 9 (17.31) |
| Platelets (<125 × 109/liter) | 4 (16.67) | 3 (10.71) | 7 (13.46) |
| Lactate dehydrogenase (>250 U/liter) | 5 (20.83) | 2 (7.14) | 7 (13.46) |
| Interleukin-6 (>7 pg/ml) | 4 (16.67) | 2 (7.14) | 6 (11.54) |
| Samples collected for SARS-CoV-2 testing (n) | |||
| Nasopharyngeal swabs | 37 | 28 | 65 |
| Sputum | 28 | 28 | |